Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer

作者：Kim Hyun Ah; Kim Eun Kyu; Kim Min Soo; Yu Jong Han; Lee Mi Ri; Lee Hae Kyung; Suh Young Jin; Noh Woo Chul^*

来源：Journal of Breast Cancer, 2013, 16(3): 266-273.

DOI：10.4048/jbc.2013.16.3.266

• Breast neoplasms
• Human epidermal growth factor receptor 2
• Radiotherapy
• Survival

Purpose: Preclinical studies have shown that human epidermal growth factor receptor 2 (HER2) status is associated with resistance to radiotherapy (RI). In this study, we evaluated the overall survival of a T1N0M0 breast cancer cohort in Korea according to the use of RT and the HER2 status. Methods: We analyzed data collected from 11,552 patients with invasive breast cancer who were enrolled in the Korean Breast Cancer Society Registration Program between 1999 and 2007. Data on the TNM stage, estrogen receptor status, progesterone receptor status, HER2 status, operation method, and the use of RT were analyzed. Results: The median follow-up period was 51 months. A significant improvement in overall survival after RI was observed only in the HER2(-) group. In this group, the 10-year overall survival rate was 95.5% for patients who did not receive RI and 96.3% for patients who received RI (p=0.037). In contrast, in the HER2(+) group, RI was not associated with a survival benefit (p=0.887). Multivariate analysis showed that RT was significantly associated with a reduction in mortality in the HER2(-) group (hazard ratio, 0.738; 95% confidence interval, 0.549-0.993; p=0.045). Conclusion: We found that postoperative RT was not associated with a survival benefit in HER2(+) breast cancer patients, suggesting that HER2(+) breast cancers could be RT resistant.

• 出版日期2013-9